In July 2024, the FDA revoked the registration of BVO in the wake of ... the agency revoked its GRAS status and limited BVO’s use to 15 parts per million in citrus-flavored beverages.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial r ...

In summary California Republicans vie to capitalize on their November victories and break Democratic supermajority while balancing Trump’s influence After flipping three seats in the state Legislature ...

Pharmexcil urges a review of a new rule for drug exports in India, which requires a product registration certificate from the importing ... which necessitates obtaining approval status from other ...

The status qualifies a drug’s sponsor for development incentives ... is devoted to the development, manufacture, registration and distribution of therapies based on cultures of epithelial stem cells ...

The National Agency for Food and Drug Administration and Control, (NAFDAC), on Wednesday, urged health sector stakeholders in the South-South region to join the fight against substandard and falsified ...

Thailand is a paradise for motorcyclists, offering some of the most stunning and diverse routes in Southeast Asia. Whether you’re a seasoned rider or someone looking for a new adventure these are some ...

Novo Nordisk’s (NVO) etavopivat was granted FDA orphan designation for treatment of thalassemias, according to a post on the agency’s ...

Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing the FDA for removing the GLP-1 medication from its shortage list.

Johnson & Johnson's nipocalimab earns FDA Fast Track status for Sjögren's disease, speeding development and review for unmet medical needs.

CAMBRIDGE, Mass. – Korro Bio, Inc. (NASDAQ:KRRO), a clinical-stage biopharmaceutical company with a market capitalization of $231 million, has received orphan drug designation from the U.S. Food ...

The FDA’s ODD status provides benefits to drug developers, including potential market exclusivity for seven years, tax credits for clinical trials, and exemptions from certain regulatory fees. This ...